{"id":57894,"date":"2023-08-15T16:06:35","date_gmt":"2023-08-15T14:06:35","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/for-the-third-time-ascellahealth-makes-the-inc-5000-at-no-850-in-2023-with-three-year-revenue-growth-of-697-73-percent\/"},"modified":"2023-08-15T16:06:35","modified_gmt":"2023-08-15T14:06:35","slug":"for-the-third-time-ascellahealth-makes-the-inc-5000-at-no-850-in-2023-with-three-year-revenue-growth-of-697-73-percent","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/for-the-third-time-ascellahealth-makes-the-inc-5000-at-no-850-in-2023-with-three-year-revenue-growth-of-697-73-percent\/","title":{"rendered":"For the Third Time, AscellaHealth Makes the Inc. 5000 at No. 850 in 2023, With Three-Year Revenue Growth of 697.73% Percent"},"content":{"rendered":"
\n

NEW YORK–(BUSINESS WIRE)–Inc. revealed today that AscellaHealth<\/a> ranks No. 850 on the 2023 Inc. 5000, its annual list of the fastest-growing private companies in America. The prestigious ranking provides a data-driven look at the most successful companies within the economy\u2019s most dynamic segment\u2014its independent, entrepreneurial businesses. Facebook, Chobani, Under Armour, Microsoft, Patagonia, and many other household name brands gained their first national exposure as honorees on the Inc. 5000.<\/p>\n

<\/a>
<\/a>
<\/a>
<\/a><\/p>\n

\n\u201cThis year’s ranking of 850 which marks our highest ranking yet, coupled with our astounding revenue growth percentage of 697.73% from 2019 to 2022 is truly a remarkable achievement!\u201d says Dea Belazi, president and CEO, AscellaHealth, LLC. \u201cOur consistent ascent on the Inc. 5000 list is evidence that our innovative solutions to address the unmet needs of patients, life sciences manufacturers, payers and providers, resulting in enhanced medication access and outcomes are being widely adopted throughout the world. With an unwavering commitment to patient-centric care, our talented team of professionals continues to raise the bar for enabling patients to achieve greater access to care and optimizing the treatment journey. The growing number of specialty and rare disease therapies, especially for individuals with complex, chronic conditions, continues to drive the growth of our global corporate footprint.\u201d<\/p>\n

\nThe Inc. 5000 class of 2023 represents companies that have driven rapid revenue growth while navigating inflationary pressure, the rising costs of capital, and seemingly intractable hiring challenges. Among this year\u2019s top 500 companies, the average median three-year revenue growth rate ticked up to an astonishing 2,238 percent. In all, this year\u2019s Inc. 5000 companies have added 1,187,266 jobs to the economy over the past three years.<\/p>\n

\nFor complete results of the Inc. 5000, including company profiles and an interactive database that can be sorted by industry, location, and other criteria, go to www.inc.com\/inc5000<\/a>. The top 500 companies are featured in the September issue of Inc.<\/i> magazine, available on newsstands beginning Tuesday, August 23.<\/p>\n

\n\u201cRunning a business has only gotten harder since the end of the pandemic,\u201d says Inc. editor-in-chief Scott Omelianuk. \u201cTo make the Inc. 5000\u2014with the fast growth that requires\u2014is truly an accomplishment. Inc. is thrilled to honor the companies that are building our future.\u201d<\/p>\n

\nBelazi continues, \u201cThe transformative impact that AscellaHealth brings to the global healthcare ecosystem is extraordinary and underscores our mission to accelerate patient pathways to diagnosis and treatment. We play a growing role in fostering collaboration among life sciences manufacturers, payers and providers, streamlining the launch and commercialization of lifesaving medications and providing the industry with novel financial solutions to advance patient access and affordability. We remain profoundly grateful for the opportunity to serve this vital mission.”<\/p>\n

\nMore about Inc.<\/i> and the Inc. 5000<\/b><\/p>\n

\nMethodology
\n
<\/b>Companies on the 2023 Inc. 5000 are ranked according to percentage revenue growth from 2019 to 2022. To qualify, companies must have been founded and generating revenue by March 31, 2019. They must be U.S.-based, privately held, for-profit, and independent\u2014not subsidiaries or divisions of other companies\u2014as of December 31, 2022. (Since then, some on the list may have gone public or been acquired.) The minimum revenue required for 2019 is $100,000; the minimum for 2022 is $2 million. As always, <\/i>Inc. reserves the right to decline applicants for subjective reasons. Growth rates used to determine company rankings were calculated to four decimal places.<\/p>\n

\nAbout Inc.
\n
<\/b>Inc. Business Media is the leading multimedia brand for entrepreneurs. Through its journalism, Inc. aims to inform, educate, and elevate the profile of our community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating our future. Inc.\u2019s award-winning work reaches more than 50 million people across a variety of channels, including events, print, digital, video, podcasts, newsletters, and social media. Its proprietary Inc. 5000 list, produced every year since 1982, analyzes company data to rank the fastest-growing privately held businesses in the United States. The recognition that comes with inclusion on this and other prestigious Inc. lists, such as Female Founders and Power Partners, gives the founders of top businesses the opportunity to engage with an exclusive community of their peers, and credibility that helps them drive sales and recruit talent. For more information, visit www.inc.com<\/a>.<\/p>\n

\nFor more information on the Inc. 5000 Conference & Gala, slated for October 31 – November 2 in San Antonio, visit http:\/\/conference.inc.com\/<\/a>.<\/p>\n

\nAbout AscellaHealth LLC
\n
<\/b>AscellaHealth, a global Healthcare & Specialty Pharmacy solutions company, serving patients, life sciences manufacturers, payers and providers, offers a comprehensive portfolio of uniquely tailored, tech-enabled services supporting complex, chronic conditions or rare diseases that require specialty medications and\/or cell and gene therapies. A recipient of numerous industry awards for innovation, and a National Association of Specialty Pharmacy Strategic Channel Partner of the Year award winner, AscellaHealth\u2019s best-in-class, patient-centric approach is built upon proprietary technology processes for novel programs and services to support the launch of specialty medications and proactively address multiple challenges, optimize clinical health outcomes, and improve quality of life for this patient population. AscellaHealth brings a rare and special perspective to all stakeholders. Visit www.AscellaHealth.com<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia:
\n
Nicole Dufour
\n
CPR Communications
\n
ndufour@cpronline.com<\/a>
201.641.1911 x 54<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK–(BUSINESS WIRE)–Inc. revealed today that AscellaHealth ranks No. 850 on the 2023 Inc. 5000, its annual list of the fastest-growing private companies in America. The prestigious ranking provides a data-driven look at the most successful companies within the economy\u2019s most dynamic segment\u2014its independent, entrepreneurial businesses. Facebook, Chobani, Under Armour, Microsoft, Patagonia, and many other … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-57894","6":"format-standard","7":"category-industry"},"yoast_head":"\nFor the Third Time, AscellaHealth Makes the Inc. 5000 at No. 850 in 2023, With Three-Year Revenue Growth of 697.73% Percent - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/for-the-third-time-ascellahealth-makes-the-inc-5000-at-no-850-in-2023-with-three-year-revenue-growth-of-697-73-percent\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"For the Third Time, AscellaHealth Makes the Inc. 5000 at No. 850 in 2023, With Three-Year Revenue Growth of 697.73% Percent - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"NEW YORK–(BUSINESS WIRE)–Inc. revealed today that AscellaHealth ranks No. 850 on the 2023 Inc. 5000, its annual list of the fastest-growing private companies in America. The prestigious ranking provides a data-driven look at the most successful companies within the economy\u2019s most dynamic segment\u2014its independent, entrepreneurial businesses. Facebook, Chobani, Under Armour, Microsoft, Patagonia, and many other ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/for-the-third-time-ascellahealth-makes-the-inc-5000-at-no-850-in-2023-with-three-year-revenue-growth-of-697-73-percent\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-15T14:06:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230815116829\/en\/1866882\/21\/Inc._5000_Primary_Black_Stacked_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/for-the-third-time-ascellahealth-makes-the-inc-5000-at-no-850-in-2023-with-three-year-revenue-growth-of-697-73-percent\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/for-the-third-time-ascellahealth-makes-the-inc-5000-at-no-850-in-2023-with-three-year-revenue-growth-of-697-73-percent\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"For the Third Time, AscellaHealth Makes the Inc. 5000 at No. 850 in 2023, With Three-Year Revenue Growth of 697.73% Percent\",\"datePublished\":\"2023-08-15T14:06:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/for-the-third-time-ascellahealth-makes-the-inc-5000-at-no-850-in-2023-with-three-year-revenue-growth-of-697-73-percent\\\/\"},\"wordCount\":845,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/for-the-third-time-ascellahealth-makes-the-inc-5000-at-no-850-in-2023-with-three-year-revenue-growth-of-697-73-percent\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230815116829\\\/en\\\/1866882\\\/21\\\/Inc._5000_Primary_Black_Stacked_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/for-the-third-time-ascellahealth-makes-the-inc-5000-at-no-850-in-2023-with-three-year-revenue-growth-of-697-73-percent\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/for-the-third-time-ascellahealth-makes-the-inc-5000-at-no-850-in-2023-with-three-year-revenue-growth-of-697-73-percent\\\/\",\"name\":\"For the Third Time, AscellaHealth Makes the Inc. 5000 at No. 850 in 2023, With Three-Year Revenue Growth of 697.73% Percent - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/for-the-third-time-ascellahealth-makes-the-inc-5000-at-no-850-in-2023-with-three-year-revenue-growth-of-697-73-percent\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/for-the-third-time-ascellahealth-makes-the-inc-5000-at-no-850-in-2023-with-three-year-revenue-growth-of-697-73-percent\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230815116829\\\/en\\\/1866882\\\/21\\\/Inc._5000_Primary_Black_Stacked_Logo.jpg\",\"datePublished\":\"2023-08-15T14:06:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/for-the-third-time-ascellahealth-makes-the-inc-5000-at-no-850-in-2023-with-three-year-revenue-growth-of-697-73-percent\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/for-the-third-time-ascellahealth-makes-the-inc-5000-at-no-850-in-2023-with-three-year-revenue-growth-of-697-73-percent\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/for-the-third-time-ascellahealth-makes-the-inc-5000-at-no-850-in-2023-with-three-year-revenue-growth-of-697-73-percent\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230815116829\\\/en\\\/1866882\\\/21\\\/Inc._5000_Primary_Black_Stacked_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230815116829\\\/en\\\/1866882\\\/21\\\/Inc._5000_Primary_Black_Stacked_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/for-the-third-time-ascellahealth-makes-the-inc-5000-at-no-850-in-2023-with-three-year-revenue-growth-of-697-73-percent\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"For the Third Time, AscellaHealth Makes the Inc. 5000 at No. 850 in 2023, With Three-Year Revenue Growth of 697.73% Percent\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"For the Third Time, AscellaHealth Makes the Inc. 5000 at No. 850 in 2023, With Three-Year Revenue Growth of 697.73% Percent - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/for-the-third-time-ascellahealth-makes-the-inc-5000-at-no-850-in-2023-with-three-year-revenue-growth-of-697-73-percent\/","og_locale":"en_US","og_type":"article","og_title":"For the Third Time, AscellaHealth Makes the Inc. 5000 at No. 850 in 2023, With Three-Year Revenue Growth of 697.73% Percent - Pharma Trend","og_description":"NEW YORK–(BUSINESS WIRE)–Inc. revealed today that AscellaHealth ranks No. 850 on the 2023 Inc. 5000, its annual list of the fastest-growing private companies in America. The prestigious ranking provides a data-driven look at the most successful companies within the economy\u2019s most dynamic segment\u2014its independent, entrepreneurial businesses. Facebook, Chobani, Under Armour, Microsoft, Patagonia, and many other ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/for-the-third-time-ascellahealth-makes-the-inc-5000-at-no-850-in-2023-with-three-year-revenue-growth-of-697-73-percent\/","og_site_name":"Pharma Trend","article_published_time":"2023-08-15T14:06:35+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230815116829\/en\/1866882\/21\/Inc._5000_Primary_Black_Stacked_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/for-the-third-time-ascellahealth-makes-the-inc-5000-at-no-850-in-2023-with-three-year-revenue-growth-of-697-73-percent\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/for-the-third-time-ascellahealth-makes-the-inc-5000-at-no-850-in-2023-with-three-year-revenue-growth-of-697-73-percent\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"For the Third Time, AscellaHealth Makes the Inc. 5000 at No. 850 in 2023, With Three-Year Revenue Growth of 697.73% Percent","datePublished":"2023-08-15T14:06:35+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/for-the-third-time-ascellahealth-makes-the-inc-5000-at-no-850-in-2023-with-three-year-revenue-growth-of-697-73-percent\/"},"wordCount":845,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/for-the-third-time-ascellahealth-makes-the-inc-5000-at-no-850-in-2023-with-three-year-revenue-growth-of-697-73-percent\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230815116829\/en\/1866882\/21\/Inc._5000_Primary_Black_Stacked_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/for-the-third-time-ascellahealth-makes-the-inc-5000-at-no-850-in-2023-with-three-year-revenue-growth-of-697-73-percent\/","url":"https:\/\/pharma-trend.com\/en\/for-the-third-time-ascellahealth-makes-the-inc-5000-at-no-850-in-2023-with-three-year-revenue-growth-of-697-73-percent\/","name":"For the Third Time, AscellaHealth Makes the Inc. 5000 at No. 850 in 2023, With Three-Year Revenue Growth of 697.73% Percent - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/for-the-third-time-ascellahealth-makes-the-inc-5000-at-no-850-in-2023-with-three-year-revenue-growth-of-697-73-percent\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/for-the-third-time-ascellahealth-makes-the-inc-5000-at-no-850-in-2023-with-three-year-revenue-growth-of-697-73-percent\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230815116829\/en\/1866882\/21\/Inc._5000_Primary_Black_Stacked_Logo.jpg","datePublished":"2023-08-15T14:06:35+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/for-the-third-time-ascellahealth-makes-the-inc-5000-at-no-850-in-2023-with-three-year-revenue-growth-of-697-73-percent\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/for-the-third-time-ascellahealth-makes-the-inc-5000-at-no-850-in-2023-with-three-year-revenue-growth-of-697-73-percent\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/for-the-third-time-ascellahealth-makes-the-inc-5000-at-no-850-in-2023-with-three-year-revenue-growth-of-697-73-percent\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230815116829\/en\/1866882\/21\/Inc._5000_Primary_Black_Stacked_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230815116829\/en\/1866882\/21\/Inc._5000_Primary_Black_Stacked_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/for-the-third-time-ascellahealth-makes-the-inc-5000-at-no-850-in-2023-with-three-year-revenue-growth-of-697-73-percent\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"For the Third Time, AscellaHealth Makes the Inc. 5000 at No. 850 in 2023, With Three-Year Revenue Growth of 697.73% Percent"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/57894","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=57894"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/57894\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=57894"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=57894"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=57894"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}